Trial Profile

Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vildagliptin (Primary) ; Insulin
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

12 May 2012 NCT reports actual patient number is 254.
12 May 2012 NCT reports actual patient number is 254.
04 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00099931).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com